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Abstract: Heart failure (HF) as a result of myocardial infarction (MI) is a major cause of fatality
worldwide. However, the cause of cardiac dysfunction succeeding MI has not been elucidated at a
sarcomeric level. Thus, studying the alterations within the sarcomere is necessary to gain insights on
the fundamental mechansims leading to HF and potentially uncover appropriate therapeutic targets.
Since existing research portrays regulatory light chains (RLC) to be mediators of cardiac muscle
contraction in both human and animal models, its role was further explored In this study, a detailed
characterisation of the physiological changes (i.e., isometric force, calcium sensitivity and sarcomeric
protein phosphorylation) was assessed in an MI mouse model, between 2D (2 days) and 28D post-MI,
and the changes were related to the phosphorylation status of RLCs. MI mouse models were created
via complete ligation of left anterior descending (LAD) coronary artery. Left ventricular (LV) papillary
muscles were isolated and permeabilised for isometric force and Ca2+ sensitivity measurement, while
the LV myocardium was used to assay sarcomeric proteins’ (RLC, troponin I (TnI) and myosin binding
protein-C (MyBP-C)) phosphorylation levels and enzyme (myosin light chain kinase (MLCK), zipper
interacting protein kinase (ZIPK) and myosin phosphatase target subunit 2 (MYPT2)) expression
levels. Finally, the potential for improving the contractility of diseased cardiac papillary fibres via the
enhancement of RLC phosphorylation levels was investigated by employing RLC exchange methods,
in vitro. RLC phosphorylation and isometric force potentiation were enhanced in the compensatory
phase and decreased in the decompensatory phase of HF failure progression, respectively. There was
no significant time-lag between the changes in RLC phosphorylation and isometric force during HF
progression, suggesting that changes in RLC phosphorylation immediately affect force generation.
Additionally, the in vitro increase in RLC phosphorylation levels in 14D post-MI muscle segments
(decompensatory stage) enhanced its force of isometric contraction, substantiating its potential in
HF treatment. Longitudinal observation unveils potential mechanisms involving MyBP-C and key
enzymes regulating RLC phosphorylation, such as MLCK and MYPT2 (subunit of MLCP), during
HF progression. This study primarily demonstrates that RLC phosphorylation is a key sarcomeric
protein modification modulating cardiac function. This substantiates the possibility of using RLCs
and their associated enzymes to treat HF.
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1. Introduction
Heart failure (HF) is a clinical syndrome where the ability of the heart to pump
blood to the rest of the body is compromised. HF arises either alone or as a combination
of dysfunctional pericardium, myocardium, endocardium, valves or major vessels [1].
Patients typically present either HF with preserved ejection fraction (HFpEF) or reduced
ejection fraction (HFrEF). As these are merely classifications of HF, HFpEF can progress
into HFrEF as the condition deteriorates. HFrEF is a more serious condition with a low
ejection fraction of <45% [1]. In general, the prevalence of HF is increasing globally, due to
an ageing population. About 64.3 million people are affected by it worldwide and 4.5% of
them are Singaporeans, while 3–4% of them are Europeans and Americans [2,3]. Recently,
increasing HF incidence in youths has been observed, potentially due to increases in obesity.
If this trend continues, the burden of HF is expected to increase [4].
The most common cause of HF is myocardial infarction (MI), which occurs as a result
of severe localised ischaemia due to blockage in the coronary artery [5]. Following MI,
the left ventricle (LV), which is primarily responsible for pumping blood throughout the
body, undergoes substantial remodelling (i.e., hypertrophy, dilation, changes in contraction
characteristics, post-translational modification of various proteins, etc.) as a compensatory
effect to sustain cardiac functionality [5–8]. However, these compensatory mechanisms
become physiologically ineffective in the long term, causing the heart to slip into the
decompensatory state [9]. The mechanisms behind the transition from the compensatory
to the decompensatory state are unclear. Given the importance of sarcomeric proteins in
muscle contraction, it is hypothesied that alterations to these proteins are the root cause of
this transition.
Aligned with the above hypothesis, a study using an MI rat model showed that the
contractile twitch force of the cardiac trabeculae correlates with the myosin heavy chain
content in end-stage HF [10], while the power output by myocardial regions unaffected
by the MI is reduced in human HF [11]. Another study by Toepfer et al., showed that
phosphorylation levels of sarcomeric proteins vary at compensatory and decompensatory
stages of HF progression [12]. These studies highlight the fact that sarcomeric protein
modifications can potentially induce cardiac functional changes during disease progression.
Thus, designing drugs targeting myofilament proteins may be a viable therapeutic approach
to alleviate the primary defects in the sarcomere under diseased state conditions [13].
In this study, we focused on myosin regulatory light chains (RLCs), as they play
an important role in cardiac physiology regulation [14,15]. RLC phosphorylation facili-
tates force production by increasing the maximal isometric tension, calcium sensitivity
of force and rate of force redevelopment at intermediate and maximal calcium activation
levels [16,17], and also enhances the motility of human beta-myosin under load as seen by
in vitro motility assays [18]. The levels of RLC phosphorylation decreased in end-stage HF
of both human and animals [19]. However, it is not known whether the changes in RLC
phosphorylation drive the functional changes during HF progression, or vice versa.
A study reported by Stull et al., showed that RLC phosphorylation potentially inhibits
pathological cardiac hypertrophy [20]. Other studies have shown that enhancement of
RLC phosphorylation in cardiac fibres increases the basal force of contraction or rescues
the pathological effects arising from mutated RLCs [11,21]. This raises the question of
whether the manipulation of RLC phosphorylation levels at a cellular level could be an
effective therapeutic strategy to reverse contractile defects during HF progression. At
the moment, there are no drugs that target RLCs directly. Propanolol was suggested to
regulate RLC phosphorylation via the inhibition of the β-adrenergic pathway. However,
it was ineffective, suggesting that the β-adrenergic pathway does not primarily influence
RLC phosphorylation [15].
In this study, we used an MI mouse model to study the time course of changes in
maximal isometric force, calcium sensitivity (EC50) and RLC phosphorylation modifica-
tions between 2D and 28D post-MI. We also manipulated RLC phosphorylation levels in
permeabilized diseased papillary fibres by exchanging native RLCs with phosphorylated
Int. J. Mol. Sci. 2022, 23, 88 3 of 24
recombinant RLCs and measured the corresponding muscle contraction to observe their
recovery. Finally, to gain mechanistic insights, we quantified the expression levels of key
enzymes (MLCK, ZIPK, MYPT2) facilitating cardiac RLC and other regulatory sarcomeric
proteins’ (TnI, MyBP-C) phosphorylation levels during HF progression.
When the longitudinal profiles of maximal isometric force and RLC phosphorylation
were superimposed, they indicate that changes in RLC phosphorylation immediately affect
force generation, in a way that promotes contractility of diseased hearts. Additionally, we
showed that enhancing RLC phosphorylation levels reverses compromised contractility in
decompensated papillary muscle segments. The longitudinal enzyme quantification unveils
the possibility of enzymes such as MYPT2 (other than MLCK and ZIPK) being involved
in regulating RLC phosphorylation levels during HF progression. The quantification of
sarcomeric protein phosphorylation and enzyme levels suggests that the resultant cardiac
functionality is a complex interplay of varying sarcomeric proteins. Bringing these results
together, we link mechanical, biochemical and physiological changes in the heart tissue
during the progression of HF. These results demonstrate that RLC phosphorylation is a key
sarcomeric protein modification that influences cardiac function during HF progression and
that RLCs and their associated enzymes have potential in the treatment and management
of HF.
2. Results
2.1. Myocardial Infarction (MI) Mouse Model Appropriate for HF Progression Study
The ligature position was optimised by experimenting at two positions, just above the
bifurcation LAD (H) or just below the bifurcation (LAD (L)) (Figure 1A). The longitudinal
contractile forces at saturating calcium concentration for the LAD (L), LAD (H) and the
control group were also monitored (Figure 1C). At 4 weeks post-MI, the contractile force
was 4.34 ± 0.3 kN/m2 when ligated at LAD (H) and 7.63 ± 0.3 kN/m2 when ligated at
LAD (L). Similarly, the force at 8 weeks post-MI was lower when ligated at LAD (H) than
LAD (L). This shows that the rate of functional deterioration is higher when ligated at LAD
(H) as compared to LAD (L). Since we aim to study HF progression over a short period of
28 days, ligating at LAD (H) will be extensive and appropriate to capture the advancement.
Thus, this position was ligated to create an MI mouse model throughout the study.
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Figure 1. LAD ligation optimisation. (A) Sche atic diagram of the ligation location. H: ligation
just above the bifurcati , L: liga ion at the l ft branch jus below the bi urcation. (B) Image of the
mouse heart with ligation at H. (C) Longitudinal comparison of contractile force following LAD (H),
LAD (L) surgery, control (no surgery) and sham surgery groups. Note: n = 3–13, where ‘n’ refers to
the umber of muscle preparations in each group from a total of 2–6 mice. Statistically insignificant
differences among the means, verified by ordinary one-way ANOVA test.
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To confirm that open chest surgery and ageing during the time course of the exper-
iments do not affect cardiac muscle contractile force, the contractile force of the perme-
abilised papillary muscle in two control groups (age-matched control and age-matched
sham surgery groups) was studied (Figures 1 and S1). The average contractile force of
permeabilised papillary muscle in the control group was 8.15 ± 2.06 kN/m2 and the aver-
age contraction force of the sham group was 7.11 ± 0.83 kN/m2. There was no significant
difference between these two groups across the 28 day experimental period. Thus, we
concluded that the changes that occurred following LAD ligation were not a consequence
of ageing, open chest surgery or the recovery from it.
To validate HF progression, key physiological and biological markers such as hy-
pertrophic indices and brain natriuretic peptide (BNP) expression levels were monitored.
Hypertrophy is the thickening of the heart due to the enlargement of cells and other al-
terations, such as extracellular matrix deposition [22]. Thus, the degree of hypertrophy
is primarily determined by the increase in heart mass. The heart mass is normalised by
the tibia length (which is consistent among populations of the same age group). The hy-
pertrophic index (heart weight/tibia length ratio) was generally higher in post-MI groups
than sham groups. However, the differences were statistically significant between the
post-MI and sham groups in 10D, 14D and 28D post-MI groups (Figure 2A). This is clearly
represented in the relative hypertrophic indices in Figure 2B.
The brain natriuretic peptide (BNP) is a cardiac neurohormone biomarker predomi-
nantly secreted by the ventricular myocardium in response to increased wall stress [23–26].
BNP is one of the gold standard techniques [27,28], alongside echocardiography, for di-
agnosis, stratifying risks and making therapeutic decisions for HF [23]. BNP expression
levels are low in age-matched control (0.102 ± 0.07). There was an increase in both 7D
(0.315 ± 0.07) and 14D post-MI (0.164 ± 0.04) when compared to their respective age-
matched control (0.102 ± 0.07) (Figure 2C). The fold change also showed that the BNP
levels at 7D post-MI were higher as compared to 14D post-MI, although statistically insignif-
icant (Figure 2D). These results were aligned with the signs of progressively failing human
hearts, where the BNP levels are higher in hypertrophic cardiomyopathy as compared to
dilated cardiomyopathy and showing very low levels in control groups [29].
Besides hypertrophic index and BNP gene expression levels, HF progression was
evaluated on a structural front. The event of hypertrophy is evident from the obvious
ventricular septal hypertrophy at 7D and 14D post-MI in histology sections (Figure 2E) [19].
On the other hand, the heart is significantly enlarged at 14D post-MI as compared to 7D
post-MI and the age-matched control (Figure 2E). These are clinical features of dilated
cardiomyopathy [20], which eventually lead to HF.
On a microstructural front, the accumulation of inflammatory molecules (in between
cardiac muscle fibres) is evident at both 7D and 14D post-MI, as highlighted by red arrows
(Figure 2F). Granulation tissues formed as a result of dead cell removal and fibroblast and
endothelial cell deposition [21] increased gradually from 7D to 14D post-MI, as indicated by
yellow arrows (Figure 2F). Some regions in post-MI samples appeared to be pale (although
inconsistent), possibly due to the disruption of sarcolemma and accumulation of water in
cardiomyocytes [11].
The results collectively showed that the hearts concurrently displayed characteristics
of hypertrophic and dilated cardiomyopathy and that the hearts failed with time (with
dilation dominating in the later stages).
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Figure 2. Physiological, biological and structural markers verifying HF progression. (A) Raw hyper-
trophic indices of post-MI and sham groups between 2D and 28D post-MI. (B) Relative hypertrophic
indic s ( ost-MI/sham verage) of post-MI group between 2D and 28D post-MI. (C) Relative BNP
gene expression levels t 7D and 14D ost-MI and s r s. (D) Fold changes in gene expression
of post-MI populations with respect to their sham groups. Note: ‘n’ refers to the number of mice.
Unpaired one-tailed t-test used to determine the differences between post-MI and sham groups. Note:
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. (B) No significant differences among the means
were verified using ordinary o e-way ANOVA. (E) Heart images and histology (Van Gieson stain) of
longitudinal heart secti ns show that the heart displays featu s of hypertrophic cardiomyopathy
at both 7D and 14D post-MI and dilated cardiomyopathy at 14D post-MI. Black arrows point to
the site of thinned left ventricular walls. Images are taken at 10×magnification. Scale bar = 1 mm.
Acronym: RV, right ventricle; LV, left ventricle; VS, ventricular septum. (F) H&E-stained, longitudinal
heart sections at 7D and 14D post-MI and age-matched control, indicating post-MI features. Red
arrows indicate site of inflammatory cell infiltration. Images were taken at 63× oil immersion and
40×magnification. Scale bar = 25 µm.
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2.2. Ca2+ Sensitivity and Calcium-Induced Cooperativity May Not Be Key Regulators of Force
Development during HF Progression
The Ca2+ sensitivity and cooperativity of myofilaments contribute to the characteristics
of cardiac contraction. EC50 is the calcium concentration at which half-maximal force is
achieved, which indicates calcium sensitivity of the contractile machinery. A lower EC50
indicates an increased Ca2+ sensitivity, as a given steady-state isometric force is reached
at a lower concentration of free calcium [30]. The Hill coefficient is the slope of the line
relating force and the negative logarithm of the calcium concentration. The steeper the
slope, the greater the cooperative activation of the sarcomeric contractile elements. This
could be such that binding of calcium to one troponin subunit increases Ca2+ affinity in the
neighbouring troponin on the same actin filament [31].
At 2D and 4D post-MI, the EC50 decreased by about 28% when compared to its corre-
sponding sham group, suggesting enhanced calcium sensitivity (Table 1 and Figure 3A).
From 7D post-MI onwards, the EC50 (half maximal effective concentration) goes back to
similar levels as the sham group, as shown in Figure 3. EC50 was also lower in the post-MI
group compared with sham at 14D and 28D post-MI. However, there is no statistical dif-
ference among these times, suggesting that calcium sensitivity may not be the main factor
influencing isometric force changes. In Figure 3B, the Hill slope shows enhanced levels
at 2D and 4D post-MI, and then decreases between 7D and 10D post-MI and increases
slightly at 14D and 28D post-MI. However, there are no statistical differences among these
timepoints, suggesting that cooperativity does not primarily influence isometric force
changes. However, it is interesting that the data collectively indicate that compensation at
4D post-MI comes with a higher calcium sensitivity and stronger calcium cooperativity.
Table 1. EC50 and Hill slopes of post-MI and sham groups.
Post-MI Group Sham Group
Time-Point 2D 4D 7D 10D 14D 28D Average of All Time Points
EC50 (µM) 1.02 ± 0.11 0.898 ± 0.11 1.43 ± 0.24 1.51 ± 0.3 1.03 ± 0.03 1.10 ± 0.05 1.34 ± 0.09
Hill Slope 1.48 ± 0.26 1.50 ± 0.11 1.2 ± 0.18 1.27 ± 0.19 1.28 ± 0.08 1.44 ± 0.19 1.25 ± 0.19
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Figure 3. Ca2+ sensitivity and cooperativity changes during MI progression. (A) Relative EC50 and
(B) relative Hill slopes (post- I a average) plotted by mouse. Each data point is the average of
at least thre muscle preparati t e cardiac papillary of one mouse. Note: n = 3–5, where ‘n’
refers to the number of mice used. One-tailed unpaired t-test was performed between timepoints.
Note: * p < 0.05 Kruskal–Wallis test was used on EC50 of samples and ordinary one-way ANOVA
was used on Hill slope of samples. There were no significant differences among the samples of the
respective groups.
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2.3. RLC Phosphorylation Transiently Changes to Sustain Cardiac Function during Compensatory
Phase of Heart Failure
The RLC phosphorylation level was lower at 2D post-MI (0.22 ± 0.01) when compared
to sham control (0.37 ± 0.02) (Figure 4Aii). The levels increased to higher than those of
sham control at 4D (0.35 ± 0.02) and 7D post-MI (0.42 ± 0.02). The phosphorylation levels
decreased below those of sham control (0.35± 0.01) from 10D post-MI (0.27± 0.04) onwards.
Similarly, the maximal isometric force decreased at 2D post-MI (5.06 ± 0.3) as compared
to its sham control (7.34 ± 0.3) and increased at 4D post-MI (11.0 ± 0.7) (Figure 4Di). At
7D post-MI (7.28 ± 0.7), the force levels were equivalent to those of the sham control
(7.31 ± 0.4). The levels decreased below the sham control (7.04 ± 0.3) from 10D post-MI
(6.38 ± 1.0) onwards. Based on the isometric force profile and structural and biological
markers for MI model verification (with reference to Section 2.1), 2D to 7D post-MI are
considered to be in the compensatory phase, while 10D post-MI onwards is considered
to be the decompensatory phase. The relative values (post-MI values normalised by
average of sham values) of RLC phosphorylation and isometric force levels are presented in
Table S1. It is important to elucidate whether the changes in RLC phosphorylation levels
drive functional changes (such as maximal isometric force) during HF progression, or
whether HF progression drives changes in RLC phosphorylation status. Thus, the sequence
of events of both parameters was superimposed. However, there is no significant time lag
observed between the two events (Figure 4E), suggesting that RLC phosphorylation levels
change transiently to enhance muscle contraction.
It was also observed that when the phosphorylation levels were between 0.35 and
0.42 mol Pi/mol RLC, the isometric force was sustained at physiologically appropriate
levels (Figure 4Aii,Di). This range is close to the baseline RLC phosphorylation levels
of ~0.3–0.4 mol Pi/mol RLC, suggesting that maintaining RLC phosphorylation levels to
baseline levels could recover cardiac contractility. To test this, the RLC phosphorylation
levels in diseased cardiac fibres were manipulated in vitro and the corresponding maximal
isometric force was measured. This is discussed in Section 2.5.
2.4. Post-Translational Modifications in Left Ventricular Tissue during HF Progression
At 2D post-MI, both RLC and TnI phosphorylation decreased significantly below
sham control levels with maximal isometric force, while phosphorylation levels of MyBP-C
increased above sham levels (Figure 4E). During what is defined as the compensatory
phase, which is between 4D and 7D post-MI, RLC phosphorylation levels were above sham
control levels, MyBP-C phosphorylation levels were below sham control levels and TnI
phosphorylation levels were maintained at sham control levels (Figure 4E). The transition
from compensatory to decompensatory stage occurred around 10D post-MI. After this,
the phosphorylation levels of MyBP-C increased above sham control levels, while RLC
phosphorylation and isometric force levels decreased below sham control levels until 28D
post-MI. TnI was maintained at sham control levels until 28D post-MI, other than a drop at
14D post-MI (Figure 4E).
Thus, the results show that the MyBP-C phosphorylation level decreases in the com-
pensatory phase and increases in the decompensatory phase. Contrary to this, the RLC
phosphorylation level increases in the compensatory phase and decreases in the decompen-
satory phase. TnI, on the other hand, shows no particular change in TnI phosphorylation
levels. The results suggest an interrelationship between RLC and MyBP-C phosphorylation
(Figure 4F), although its underlying mechanisms are unknown. The longitudinal profile
also shows that the MyBP-C phosphorylation pattern presents a progression that is opposite
to the isometric force profile (Figure 4E), which is contrary to the current observations. The
protein phosphorylation levels are summarised in Table S1.






































































































































































Fig r . it dinal sarcomeric protein phosphorylatio and maximal isomet ic force m asure-
ments during HF progression. (Ai,Bi,Ci) Blot images of RLC, MyBP-C and TnI phosphorylation
levels of post-MI and sham groups at different time points ranging between 2D and 28D post-MI,
respectively. (Aii,Bii,Cii,Di) Bar graphs of RLC, MyBP-C and TnI phosphorylation and maximal
isometric force of post-MI and sham groups at different ti e points ranging between 2D and 28D
post-MI. U paired on -tailed t-t st (*) was onducted on parametric and homogenous population.
Unpaired one-tailed t-test with Welch’s correction (*) was conducted on parametric but inhomoge-
neous population. Unpaired one-tailed Mann–Whitney test (#) was conducted on non-parametric
population. Number of mice used is summarised in Table S1. Note: ‘n’ refers to the number of techni-
cal replicates. (Aiii,Biii,Ciii,Dii) Bar graphs for relative RLC, MyBP-C and TnI phosphorylation and
maximal isometric force values duri g HF progression, respectively. Kruskal-Wallis ANOVA test
was p rformed on RLC pho phorylation populations and showed that the medians varied signifi-
cantly (* p = 0.0102). Ordinary one-way ANOVA performed on MyBP-C phosphorylation showed
significant differences in the means (**** p < 0.0001). Ordinary one-way ANOVA performed on TnI
phosphorylation showed significant differences in the means (** p < 0.01). Ordinary one-way ANOVA
performed on isometric force data showed significant difference among population means (p < 0.0001).
(E) Line graph of relative phosphorylation levels of all three sarcomeric proteins and isometric force.
(F) Line grap of relative phosphorylation levels of RLC and MyBP-C. Not : * p < 0.05, ** p < 0.01,
*** p ≤ 0.001, **** p < 0.0001, # p < 0.05, ## p < 0.01.
The correlatio between the changes of the respective sarcomeric protein phosphory-
lation levels and isometric force was an lysed using Spearman’s correlation te t. There is
a stro g and negative correlation b tween MyBP-C phosphorylation and isometric force
(r = −0.94), which is statistically significant (T ble S2).
2.5. Modulation of th Phosphorylation Lev l of RLC Induces R covery of the Contractile
Performance of Papillary Muscle In Vitro
To exp ore the potential of RLC phosphorylation in reversing diseased muscl con-
tractility, phosphorylated recombinant RLCs were exchanged (in vitro) into permeabilised
papillary muscles isolated from 14D post-MI mice hearts. After the exchange procedure, the
phosphorylation levels in 14D post-MI fibres were enhanced from 0.09 ± 0.04 mol Pi/mol
RLC to 0.33± 0.007 mol Pi/mol RLC (Figure 5Aii). However, it was not possible to enhance
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the phosphorylation levels to match 14D sham (non-exchanged) papillary segments. The
maximal isometric force of 14D post-MI fibres was increased from 3.95 ± 0.2 kN/m2 to
6.20 ± 0.2 kN/m2 after the exchange procedure (with 25 mM P-RLC, 27 mM TnC). How-
ever, the force produced did not recover to match the force produced by 14D sham papillary
(non-exchanged) segments (Figure 5B). This could be due to RLC phosphorylation levels not
being enhanced to suitable levels (0.35–0.42 mol Pi/mol RLC), as mentioned in Section 2.3.
Nonetheless, in permeabilised muscle models where other signalling mechanisms are
disrupted, increased RLC phosphorylation levels are able to enhance the isometric force of
contraction. The phosphorylation and force values are summarised in Table S3.
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Figure 5. Potential for orylation in terms of muscl recovery. (Ai) Blot images of RLC
extracted papillary muscle fibres under two treatments: 14D sham and post-MI permeabilized fibres
(control) and 14D post-MI and sham permeabilized fibres exchanged with phosphorylated RLCs.
Each lane contains protein samples extracted from five papillary fibre segments. (Aii) Bar graph
representation of phosphorylation levels for the above-mentioned groups. Unpaired one-tailed
Mann–Whitn y est wa performed for he respect ve groups, but no significant dif e ence was
detected between the ranks. Note: ‘n’ refers to the technical replicates. Two mice were used for
post-MI groups and one mouse was used for sham group. (B) Bar graph of maximal isometric force
of the above-mentioned groups. Unpaired one-tailed t-test was conducted to test for statistically
significant differences. Three mice were used for each group. Note: ‘n’ refers to the number of
papillary segments used for data collection; ** p < 0.01, **** p < 0.0001.
2.6. Enzyme Quantification of Left Ventricular Tissue during HF Progression
From the longitudinal experiments conducted, the normalised expression levels
showed that MLCK gradually increased from 2D to 7D post-MI and decreased there-
after (Figure 6Aii,D), which corresponds with the compensatory and decompensatory
changes in RLC phosphorylation profiles in post-MI samples. A significant increase was
detected at 7D post-MI from 2D post-MI, where RLC phosphorylation was highest during
HF progression. On the other hand, the expression levels of sham populations fluctuated
and no clear pattern was observed (Figure 6Aii).
A gradual decrease in the normalised ZIPK expression levels was observed from 2D
post-MI onwards in post-MI samples (Figure 6 Bii,E), suggesting t at ZIPK does not directly
contribute to the compensatory increase in RLC phosphorylation during HF progression.
However, this may contribute to the decrease in RLC phosphorylation in late-stage HF.
ZIPK expression levels of sham populations, on the other hand, seemed to increase very
gradually from the timepoint of 2D post-MI, although the differences among the means of
all timepoints were not statistically significant (according to ANOVA test).
The longitudinal normalised MYPT2 expression levels in post-MI samples depicts a
profile that is inverse to normalised MLCK expression levels. It is interesting to note that the
significant decrease in the expression levels at 7D post-MI directly relates to the largest com-
pensatory increase in the RLC phosphorylation levels. On the other hand, the expression
levels of sham population fluctuated, and no clear pattern was observed (Figure 6Cii,F).
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MYPT2, respectively. (Aii,Bii,Cii) Bar graph of normalised MLCK, ZIPK and MYPT2 amounts of
post-MI and sham populations, respectively. All sample populations are normally distributed and
validated by Shapiro–Wilk test. Differences in the standard deviations between two timepoints were
tested by F-test. Unpaired one-tailed t-test with Welch’s correction (*) was performed on those with
significant differences in the variances, while unpaired one-tailed t-test (*) was performed for all other
samples. Note: n = 3–6, derived from at least two mice for post-MI and three mice for sham (except
7D sham, where one mouse was used). Note: ‘n’ refers to the number of technical replicates; * p < 0.05,
** p < 0.01. (D–F) Line graph plotted with normalised enzyme values and RLC phosphorylation to
depict longitudinal changes in post-MI and sham populations.
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To identify the key enzyme(s) responsible for the changes in RLC phosphorylation
during HF progression, the changes in each enzyme expression level were compared to the
changes in RLC phosphorylation at each timepoint. Focusing on post-MI samples, the ex-
pression levels of all three enzymes decreased at the 4D post-MI timepoint, corresponding
to significant decreases in RLC phosphorylation levels from 2D post-MI timepoint (Table 2).
The statistically significant decrease in MYPT2 was expected to cause an increase in the net
phosphorylation. However, the reverse was observed. Thus, the decrease in the resultant
phosphorylation implies that the coaction of MLCK and ZIPK has a greater effect than
MYPT2. On the other hand, the expression levels of all three enzymes increased at the
28D post-MI timepoint, corresponding to a significant decrease in RLC phosphorylation. It
is postulated that the statistically significant increase in MYPT2 caused a decrease in the
net phosphorylation. In this case, however, the decrease in the resultant phosphorylation
implies that the coaction of MLCK and ZIPK has a lesser effect than MYPT2, which contra-
dicts the hypothesis made previously. Referring to another example in post-MI samples,
at 14D and 28D post-MI, the significant increase and decrease in ZIPK expression levels,
respectively, resulted in the phosphorylation levels decreasing and remaining unchanged,
respectively. Thus, the significant changes in enzymes did not always bring about the
expected phosphorylation effect.
Table 2. Summary of changes in the enzyme expression levels in post-MI and sham populations of
mice. Arrows represent increases or decreases in normalised enzyme expression or RLC phosphory-
lation with respect to the previous timepoint. Note: ‘-’ indicates no change from previous timepoint.
Asterisks indicate significant changes from the previous timepoints, validated by unpaired one-tailed
t-test or with Welch’s correction. Note: * p < 0.05, ** p < 0.01, **** p < 0.0001.
Sham Samples 4D 7D 14D 28D
MLCK ↓ ↑ ↓ ↑
ZIPK ↓ ↑(**) - ↑
MYPT2 ↓(**) ↑(*) ↓(*) ↑(*)
RLC Phosphorylation ↓(**) ↑(*) ↑ ↓(*)
Post-MI samples 4D 7D 14D 28D
MLCK ↑ ↑ ↓ ↓
ZIPK ↓ ↓ ↑(*) ↓(**)
MYPT2 ↑ ↓(**) ↑ ↑
RLC Phosphorylation ↑(****) ↑(*) ↓(****) -
Thus, the primary enzymes that brought about net RLC phosphorylation were unable
to be elucidated based on the significant change in abundance, although the changes in
the MLCK and MYPT2 expression levels were closely related to the RLC phosphorylation
profiles. Nonetheless, these results clearly show that the net RLC phosphorylation is a com-
plex interplay of various enzymes’ actions. Moving forward, it will be essential to explore
the enzyme activity to elucidate the key enzyme(s) involved. A better understanding of
the fundamental roles of enzymes such as ZIPK and MYPT2 will also allow for a more
complete interpretation of these results. To isolate the roles of the individual enzymes, other
forms of study models (e.g., causative models such as gene knockout) must be employed.
2.7. Differential RLC Expression in Left Ventricular Tissue during HF Progression
In this HF longitudinal study, the RLC amounts gradually increased from 2D to 7D
post-MI and decreased thereafter (Figure 7B), while RLC amounts of sham samples were
relatively stable (Figure 7C). There was a significant increase in RLC amounts at 4D and
7D post-MI from 2D post-MI (Figure 7B), which is defined as the compensatory phase in
Section 2.3. Additionally, when the normalised amounts are superimposed (Figure 7D),
the increase in RLC amounts at 7D post-MI is statistically significant. This opens another
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perspective of reasoning regarding the cardiac functional changes during HF progression
(especially during the compensatory phase); that is, whether it is primarily due to the
changes in RLC phosphorylation levels or the absolute amount of RLCs in the heart.
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Fig re 7. Changes in the quantity of RLCs suggesting losses in diseased mouse sarcomere.
(A) Blot image of RLC of post-MI and sham groups at different time points ranging between 2D and
28D post-MI. (B) Bar graph of normalised RLC amounts at different time points for post-MI groups.
Unpaired one-tailed t-test with Welch’s correction (*) was used between 2D and 4D, 2D and 7D and
4D and 7D samples. Mann-Whitney one-tailed test (#) was performed between 7D and 28D samples.
Kruskal-Wallis test indicated that the medians varied significantly among samples (p = 0.0194). All
samples were normally distributed (except 28D post-MI), as validated by Shapiro-Wilk test. There
were significant differences in the standard deviations, except between 4D and 7D post-MI and 7D
and 28D post-MI, as validated by F-test. Results were obtained from at least two mice for post-MI
samples. Note: n = 4–9, where ‘n’ refers to the number of technical replicates; * p < 0.05, ** p < 0.01,
*** p < 0.001, # p < 0.05. (C) Bar graph of normalised RLC amounts at different time points for sham
groups. Ordinary one-way ANOVA showed no signific nt differences among population means.
Sample populations wer nor ally distributed, as validated by Shapiro-Wilk test. No statistical
significance detected between timepoints, validated by F-test. R sults were obtained from one mouse
for sham samples. Note: n = 5–8, where ‘n’ refers to the number of technical replicates. (D) Superim-
posed graph of post-MI and sham samples. Unpaired one-tailed t-test with Welch’s correction was
performed on 7D samples.
3. Discussion
Heart failure (HF) aetiologies include ischaemic (coronary artery disease, myocardial
infarction), hypertensive (HFpEF—heart failure with preserved ejection fraction; HFrEF—
heart failure with reduced ejection fraction) and primary cardiomyopathies (genetic, stress
induced, etc.) [32,33]. However, epidemiological studies have shown that ischaemic heart
disease (IHD) is a common cause of HF with a poor prognosis [34–36]. Thus, pathophysio-
logical changes during ischaemia-induced HF progression were explored in this study with
the use of the LAD-ligated MI mouse model. Past studies reported that hypertrophy was
evident from 4D post-MI, that the ventricle wall became thinner from 7D post-MI [37] and
Int. J. Mol. Sci. 2022, 23, 88 13 of 24
that dilated hypertrophy develops from 4 weeks post-MI if the infarction is extensive [12]
upon LAD ligation.
The choice of animal model and strain is extremely important to successfully model
diseases, and in this case to recapitulate HF progression within a short time period. This
is because species or different strains of a species can result in varying outcomes [38,39].
For example, even though decreased RLC phosphorylation levels are mostly associated
with severe heart failure [40,41], there are studies that report that RLC phosphorylation
continued to increase in end-stage HF in humans and rats [11,12]. On the other hand,
when the LAD coronary artery was ligated to induce ischaemic injury, BalbC strain led to
extensive thinning of the ventricular and septum walls, while 129S6 strain was most prone
to infarct rupture by the endpoint of 28D post-MI. These results show that the different
substrains can be used for studying different disease models [38]. C57BL/6 is useful for
studying HF progression, as it displays characteristics (wall thinning, cardiac dilation,
reduced ejection fraction) of a failing heart by 28D post-MI [38,39], while rats take longer
at 20–32 weeks post-MI [42], where MI is induced by coronary artery ligation. C57BL/6
also displays relatively low incidence (36%) of myocardial rupture [38], making it useful
for studying the functional and molecular changes over longer periods post-MI, with low
attrition rates. Apart from the ability to manifest the characteristics of a failing heart post-
MI, as presented in Section 2.1, the use of mice is advantageous due to their relative low
cost, reproducibility, well-established genome and ability to be genetically modified [43].
LAD occlusion lower down in the coronary artery tree, referred to as LAD (L) in the present
study, has an almost 0% fatality rate but only showed significant damage 8 weeks post-
ligation. If the ligation position is too high, the fatality rate can be nearly 70%, although
induction of visible MI damage is accelerated. In this study, LAD occlusion was performed
at a high position, referred to as LAD (H), with ligation just above the bifurcation (1–2 mm
below the tip of the left auricle). The results of surgery were reasonably repeatable and
consistent, despite the fact that there were visible variations in the arrangement of the
coronary tree from animal to animal.
Based on the hypertrophic index, hypertrophy was noticeable throughout HF progres-
sion. However, the gradual decrease in hypertrophic indices in the later stages indicated
the possible dominance of cardiac dilation characteristics. The BNP expression levels were
aligned with the signs of progressively failing human hearts, where the BNP levels were
higher in hypertrophic cardiomyopathy as compared to dilated cardiomyopathy, with
very low levels in control groups [29]. These features were aligned with features of failing
human hearts, where hypertrophy was dominant in the initial stages as a compensatory
mechanism to preserve cardiac function and dilation of the chambers in the later stages [44].
These were supported by the dilated phenotype observed from structural observation
via histology.
Here, we provide a detailed time-course of changes in functional (Ca2+ sensitivity
and cardiac contractility) and molecular (sarcomeric protein phosphorylation and enzyme
expression quantification) characteristics, which have not been reported before. Dissecting
the sequence of molecular changes during the time course is critical for treatment and
drug development. For example, early medical interventions (within 24 h) include the use
of angiotensin-converting enzyme inhibitors and the use of aldosterone antagonists for
HF therapy following MI (within 7 days). However, early use (<24 h) of beta-blockers is
associated with an increased risk of cardiogenic shock and death. Delayed beta-blocker
administration post-MI is associated with a reduced risk of re-infarction and death [45].
Converging on Ca2+ sensitivity, it is the characterisation of the relationship between
the calcium ions available for Troponin C binding and the amount of force generated by
the muscle [30]. In the failing myocardium, calcium sensitivity has been reported to an
either increase or decrease depending on the etiology of the disease [46]. In our study,
calcium sensitivity and co-operativity increased (indicated by a lower EC50 and a higher
Hill slope) at 2D and 4D post-MI groups when compared to its sham group. The gradient of
the Hill slope indicates the Ca2+ dose response. Thus, a higher gradient indicates stronger
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co-operativity. However, there were no statistically significant differences in the data
from 7D post-MI onwards, indicating a loose correlation between calcium sensitivity and
contractile force, likely dependent on the stage of HF. In a previous study published by
our lab, although the calcium sensitivity was not established, we found that the contractile
force in the compensatory phase of HF (MI rat model) increased even in saturating calcium
conditions (32 µM). This suggests that the increase in force compared tothe sham group
could not be attributed to a change in calcium sensitivity [12]. On the contrary, other
reports showed that mutations associated with hypertrophic cardiomyopathy (HCM) and
restrictive cardiomyopathy (RCM) displayed increased Ca2+ sensitivity of force production,
while mutations associated with dilated cardiomyopathy (DCM) demonstrated a decreased
Ca2+ sensitivity of force production. One possible reason for myofibrillar Ca2+ sensitivity
being higher in a failing heart than in a non-failing heart (with a 2–3-fold lower EC50)
could be lower levels of Troponin I phosphorylation [47]. Another argument is that heart
failure is associated with an early increase in Ca2+ sensitivity that reverts to decreased Ca2+
sensitivity at the end-stage of heart failure. Although we showed a pattern of increased
and decreased Ca2+ sensitivity in our MI mouse model, these data are not conclusive and
require further study [48]. However, we limit our interpretation to RLC phosphorylation to
explain the change in contractile force at saturating calcium concentration.
To benefit from the advantages of RLC and its phosphorylated form, its role in HF
development needs to be understood comprehensively. RLC phosphorylation levels are
significantly reduced in heart failure patients [49–51], and the levels do not differ between
dilated and ischaemic hearts [50,51]. On the other hand, in rats, the phosphorylation levels
continue to increase at 20 weeks post-MI (decompensatory phase) [12], while rabbits expe-
rience a continuous decrease at 2 weeks post-MI [52]. Thus, there is no clear pattern in the
variation of RLC phosphorylation during HF progression. Nonetheless, due to the ability
of RLC phosphorylation to enhance contractility, it is postulated that RLC phosphorylation
increases during the compensatory state and decreases during the decompensatory state.
We also do not know whether RLC phosphorylation drives the functional changes during
HF progression or whether the development of HF drives the RLC phosphorylation levels.
Thus, the maximal isometric force potentiated by papillary fibres was measured at the
different timepoints during HF progression. Papillary muscles closely represent the func-
tionality of the heart, as studies showed that they lose contractility with MI and also thicken
when the heart experiences hypertrophy [53]. Additionally, RLC phosphorylation in the left
ventricular muscles was quantified. The longitudinal profiles of maximal isometric force
and RLC phosphorylation levels during HF progression were superimposed. However,
no significant time lag was identified, suggesting that RLC phosphorylation levels change
transiently to enhance cardiac functionality during the compensatory phase of HF. This
is contrary to the event of RLC phosphorylation in beating hearts where the levels are
stable [54], suggesting a physiological change could have occurred due to MI.
The baseline RLC phosphorylation levels are regulated by the activities of cardiac
myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP). It is likely
that alterations or disruption to the activation of these (or other) enzymatic pathways
could have resulted in the deviation from the baseline levels. Supporting this, a study
has reported that MLCK levels were significantly decreased 3 weeks post-MI in an HF
mouse model [55]. The phosphorylation of cardiac isoforms occurs on a minute timescale,
while smooth and fast skeletal RLCs are phosphorylated on a timescale of seconds in
response to stimuli [54,56–58]. The heart is made of cardiac-specific fibres, with no other
muscle isotypes, such as smooth, fast-twitch or slow-twitch skeletal muscle [59]. Other
isoforms of RLCs are also not present in cardiac muscles [56]. This implies that the ability to
capture the variations in phosphorylation profiles on a timescale of hours could be due to
slower upstream signalling pathways. Even though the underlying mechanisms for these
changes are unknown, it is apparent that the natural cardiac physiology has attempted to
induce a compensatory effect to sustain cardiac function. The structural and contractile
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characteristics collectively indicate the compensatory phase to be between 4D and 7D
post-MI, while the decompensatory phase is between 10D and 28D post-MI.
Our results also show that when phosphorylation levels were between 0.35 and
0.42 mol Pi/mol RLC, the isometric force was sustained at physiologically appropriate
levels. This range is close to the baseline RLC phosphorylation levels of ~0.3–0.4 mol
Pi/mol RLC, suggesting that maintaining RLC phosphorylation levels to baseline levels
could recover cardiac contractility. It has been established that enhanced RLC phospho-
rylation levels in permeabilized striated muscle fibres improve muscle contractility and
phosphorylation of R58Q, while A13T mutated RLC restores Ca2+ binding to RLC [57].
Similarly, when the procedure was employed in 14D post-MI permeabilized papillary fibres,
the phosphorylation levels increased by 72.6% and the force of contraction increased by
57%. This finding was key in substantiating the possibility of using phosphorylated RLCs
in cardiac disease treatment by improving cardiac contractility, as contractility alongside
heart rate substantiates the basic functionality of the heart [58].
This study also opens up another perspective of reasoning regarding the cardiac func-
tionality changes during HF progression relating to the changes in the amount of RLCs
during HF progression. A study published in 1992 showed that RLC amounts in human
hearts were significantly reduced in idiopathic dilated cardiomyopathy, possibly due to
protease-mediated cleavage of RLC [60]. Another study showed that the ELC/RLC ratio
was maintained between healthy and failing hearts. However, there were no comments
on the absolute amounts of RLCs [50]. In our results, the RLC amounts were enhanced
in the compensatory phase, suggesting that the increase in RLC amounts could improve
cardiac function. It is known that RLC levels are precisely regulated by post-transcriptional
mechanisms based on a study of overexpressed RLC mRNA and unchanged RLC pro-
tein levels [61,62]. The reasons underlying the changes in RLC expression during HF
progression are unclear. However, based on the above-mentioned studies, the changes
could be due to a disruption in the protease-mediated cleavage or post-transcriptional
cellular mechanisms.
The downstream enzymes (kinases and phosphatases) play a key role in regulating
phosphorylation levels. On that note, ZIPK, MLCK and MLCP are known to be directly
involved in regulating RLC phosphorylation. According to the literature, the levels of
MLCK and ZIPK are expected to decrease during HF progression, while the patterns
of MLCP expression during cardiac disease or HF have not been reported [9,55,63]. It
is established that basal cardiac RLC phosphorylation levels are regulated primarily by
cardiac myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP) in
humans and animals such as mice, rats and pigs [15,64,65]. In MLCK knockout mice, the
cardiac RLC phosphorylation levels decreased to 10% and heart failure was developed [15].
In MI mouse models, both cardiac MLCK and RLC phosphorylation levels were reduced
in HF tissues (3 weeks post-MI) as compared to control [55]. While MLCK mRNA levels
in mice were sustained in failing hearts [55], the levels increased in humans and rats [65],
indicating variations in the transcription process. Our results show that MLCK expression
is generally increased until 7D post-MI and decreases thereafter, which corresponds to RLC
phosphorylation profiles. However, the activity of these enzymes needs to be monitored to
elucidate the underlying pathways.
Studies have shown that other kinases are also able to phosphorylate RLCs. A promi-
nent enzyme is ZIPK, a 52.5 kDa serine/threonine kinase, also known as death-associated
protein kinase 3 [66], which is ubiquitously expressed in human and mouse hearts [67,68].
Ventricular RLC is a prominent substrate of ZIPK, as identified by an unbiased substrate
search on heart homogenates [69]. Biochemical analysis confirmed that ZIPK phospho-
rylates the Ser-15 residue in mouse and human RLCs [69]. ZIPK also regulates RLC
phosphorylation levels by activating myosin light chain phosphatases via direct phospho-
rylation [70]. However, its activation and role in cardiomyocytes are unknown [69]. The
changes in basal RLC phosphorylation levels were not associated with any changes in
ZIPK levels [71]. However, lower levels of ZIPK expression were observed in the hearts
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of patients with dilated cardiomyopathy [9,63]. Aligned with the literature, our results
demonstrate that ZIPK expression continually decreases during HF progression. Our
results also show that ZIPK expression does not directly contribute to the increase in RLC
phosphorylation during the compensatory stage.
The baseline RLC phosphorylation levels in healthy hearts are maintained as MLCPs
work concurrently [15] with the kinases. Striated muscle MLCPs are composed of a regula-
tory targeting subunit (MYPT2, 110–130 kDa), a catalytic subunit (PP1cδ, 38 kDa) and a
small subunit (hHS-M21) with an unknown function [54,72,73]. MYPT2 interacts with PP1cδ
to target myosin filaments and potentiate phosphatase activity in striated muscles [74,75].
In wild-type mice, 100% of the MYPT2 was constitutively and maximally phosphorylated
at Thr646 (responsible kinase is unidentified) in beating hearts [15,76,77]. This constitu-
tive phosphorylation is predicted to be an intramolecular autoinhibition mechanism [78].
The MYPT2 dephosphorylation mechanism and the profile of phosphorylated MYPT2 in
diseased hearts have not been elucidated yet [15,76]. In this study, when both wild-type
and post-MI groups were resolved in phos-tag gels and blotted, only one band of protein
was observed, meaning all MYPT2 types are assumed to be phosphorylated. In our results,
MYPT2 expression gradually decreased until 7D post-MI, when RLC phosphorylation was
the highest, and then increased thereafter.
The quantification and correlation of enzymes collectively suggest that MLCK and
MYPT2 regulate RLC phosphorylation through the compensatory and decompensatory
phases, while ZIPK potentially contributes to the decompensatory phase only.
Cardiac RLCs are also phosphorylated by protein kinase C (PKC) via the activation of
the α-adrenergic pathway. PKC phosphorylates at different sites from MLCK [79]. CaM-
dependent kinase II (CaMKII) phosphorylates RLCs under inotropic effect [80]. Rho-kinase
(ROCK) indirectly (via stimulation of α-adrenergic receptors) increases RLC phosphoryla-
tion levels by inhibiting MLCP activity via phosphorylation of a fragment (MYPT2) [14,81].
However, these kinases do not only phosphorylate RLCs but also other sarcomeric proteins,
such as troponin I (TnI) and cardiac-myosin-binding protein C (MyBP-C).
On that note, it is undeniable that other sarcomeric proteins co-regulate muscle con-
traction, and it is important to study their role in HF progression. Our results suggest that
RLC phosphorylation is directly correlated while MyBP-C phosphorylation is inversely
correlated to isometric force. The latter is contrary to the current understanding of MyBP-Cs.
Most studies report a decrease in MyBP-C phosphorylation levels in end-stage HF. For
example, mice that had been genetically or surgically (transaortic constriction/ischaemic-
reperfusion) modified to develop stressed hearts and failing human myocardium displayed
increased dephosphorylated MyBP-C levels, which were related to contractile dysfunc-
tion and heart failure [82–85]. However, on the other hand, another study with an MI
rat model displayed increased cMyBP-C phosphorylation levels in the decompensatory
phase at 4 weeks post-MI and 20 weeks post-MI, respectively [12]. Similarly, the MyBP-C
phosphorylation levels increased from 14D post-MI onwards in this longitudinal study.
The rationale behind these discrepancies is unclear. However, a possible reason could be
differences in the strains of mice or species used for experimentation, resulting in differen-
tial G-protein coupled receptor activation [86,87]. Nonetheless, the decrease in MyBP-C
phosphorylation (where phosphorylation is known to induce ionotropic effects) during the
compensatory phase is unexplainable at the moment. On the other hand, the opposite phos-
phorylation profiles of RLC and MyBP-C during HF progression are thought-provoking, as
they present the possibility of phosphorylation activity being affected by spatial hindrance
due to the alignment of the molecules [88].
Our results show no particular change in TnI phosphorylation levels during HF pro-
gression. This is similar to a rat ischaemic mouse model presented in another study [12].
However, TnI phosphorylation levels are significantly decreased in failing human
hearts [85,89,90]. TnI is phosphorylated by multiple kinases, and these kinases are ac-
tivated by various signalling pathways [91]. Some of these kinases phosphorylate specific
sites activating ionotropic effects, while other kinases phosphorylate other sites produc-
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ing an opposite effect, such as a reduced cross-bridge cycling rate [91,92]. For example,
phosphorylation of Ser22/23 of TnI by PKA in mice increases the cross-bridge cycling
rate [91], while phosphorylation of Ser43/45 of TnI by PKC decreases the cross-bridge
cycling rate [91]. Thus, there is a possibility that the almost stabilised phosphorylation
levels between 4D and 28D post-MI represent an attempt of the kinases and phosphatases
to achieve a phosphorylation profile to induce inotropic (compensatory) effects [91,92].
There is also evidence of desensitisation of G-coupled protein receptors during heart failure,
which affects the activation of downstream enzymes [90]. These could have influenced the
resultant phosphorylation profile.
The complexity of the underlying mechanisms resulting in the compensatory and
decompensatory phases is extensive. Moreover, proteomic and phosphoproteomic studies
on cardiac muscle during HF [93,94] have not been extensively explored. This is important
to establish therapeutics for cardiac diseases. In a recent publication, a potential treatment
by altering cross-bridge dynamics using Mavacamten (oral treatment targeting cardiac
specific myosin) was reported. This was demonstrated on muscle fibres isolated from
hearts experiencing hypertrophic cardiomyopathy [95,96]. Similarly, the in vitro effects of
the phosphorylation of RLC or other sarcomeric proteins can be appropriately exploited to
manipulate cardiac muscle function in vivo. However, more investigation is needed on the
cellular mechanisms prior to progressing to advanced in vivo models.
On a technical front, our experience and those of others show that it is inaccurate to rely
on an internal control protein for C57BL/6 mouse MI models [97]. This is because common
housekeeping proteins such as GAPDH and β-actin express differentially at different stages
of ischaemic myocardial injury [97]. Similarly to the literature, in our experiments, the
GAPDH amounts are generally lower in post-MI groups as compared to their age-matched
controls, with statistically significant differences between 14D post-MI and age-matched
control populations (Figure S4). Hence, equal amounts of total proteins, as calculated
by BCA protein assay kit, were loaded per lane as loading controls. Besides using total
proteins as loading controls, phosphorylation results were obtained by normalising the
phosphorylated protein amounts by their respective total protein amounts. For experiments
studying the protein abundance, the protein intensities were normalised to a common
factor (e.g., 2D sham or 2D post-MI) within the blot. These measures were taken to ensure
reliable and accurate representation of the results.
4. Materials and Methods
4.1. Generation of Chronic Myocardial Infarction (MI) Mouse Model
Animal experiments were carried out in accordance with the guidelines of the Uni-
versity Institutional Animal Care and Use Committee (IACUC, ARF-SBS/NIE-A0354),
Singapore. C57/BL6 male mice aged 4–5 weeks were used for data collection. In prepa-
ration for surgery, the mice were placed supine on a temperature-regulated surgical table
at 37 ◦C ± 0.5 ◦C. Ventilation via endotracheal tube was maintained with 100% oxygen
using a small animal ventilator (Hugo Sachs, March, Germany) delivering a tidal volume
of 7 µL/g at 200 breaths/min. An incision in the skin was made left of the prominent
xiphoid cartilage. Skin and muscle layers were gently separated to expose the 3rd and
4th ribs. The intercostal space was opened following the natural angle of the ribcage and
retracted to expose the heart. The pericardium was gently picked up and pulled apart. The
LAD coronary artery was then identified, and with a 9–0 suture, ligated with three knots
approximately above the bifurcation (H), as shown in Figure 1A. The bottom left portion of
the left ventricle clearly bleached and the heart rate increased for a short period (~3–5 s)
upon successful ligation. The chest cavity was closed with one or two 5–0 nylon sutures
(Greenwood R&D support Pte. Ltd., Singapore) and the muscles and skin were closed
layer-by-layer with 5–0 nylon sutures. A 1 mL syringe attached to a 25-gauge needle was
then inserted about 5 mm below the ribcage to remove the air trapped in the chest cavity
by pulling the plunger gradually. This helped the mice to develop a regular breathing
pattern and prevented the occurrence of pneumothorax. Buprenorphine (0.1 mg/kg) was
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intramuscularly injected into the mice at a dose of 0.1 mL/10 g to manage post-operative
pain [98]. The intubation needle was removed when the effects of isoflurane subsided. This
was confirmed by gently pinching toes to check for recovery of reflex responses, such as
pedal withdrawal [99]. Buprenorphine was administered for the next two days to ease any
pain experienced by the mice. The sham-operated mice underwent the same procedure
except for tying knots to occlude the artery.
4.2. Papillary Preparation for Maximal Isometric Force and Ca2+ Sensitivity Measurements
Papillary muscles were used as surrogate cardiac muscle in the undamaged region
of the heart. The anterior and posterior ventricular papillary muscles from mouse hearts
were isolated according to the methods described before with minor modifications (see
Supplementary Materials) [12]. Briefly, each isolated papillary muscle was divided into
3 segments measuring 2 mm in length and 150 µm in diameter. The ends of the muscle
segments were crimped with aluminium T-clips and were held at just beyond slack length. The
segments were then permeabilised with 1% Triton overnight. This resulted in the perforation of
the cellular and organelle membranes, allowing chemicals to penetrate. The demembranation
also resulted in the loss of enzymes and enzyme-mediators. Thus, the phosphorylation status
of the sarcomeric proteins was unaffected by the permeabilisation process [100,101].
Prior to force measurements, the permeabilised papillary segments were attached
to the experimental rig by hooking the ends to a customised force transducer (AE801,
Kronex, Oakland, CA, USA) and a servomotor in a 6-trough stage [11]. The initial force
(normalised to the cross-sectional area of the muscle segment) of all segments in the relaxed
state was offset to 2 kN/m2 in relaxing solution by adjusting the length of the preparation.
In practice, the muscle segments were allowed to stabilise in relaxed buffer for 3 min
before being transferred to the pre-active buffer. The muscle segments were transferred
to the pre-activating buffer by rotating the stage so that the length remained and was
incubated for 3 min to prime the muscles for active contraction. For the measurement of
maximal isometric force, the muscle segments were transferred to an experimental trough
containing activating solution with 5 mM Mg2+ ATP and saturating calcium concentration
(32 µM) and then incubated for 3 min (to ensure the active buffer is optimally diffused into
the muscle fibre). By then, the plateau of the maximal isometric force was reached and
recorded using LabVIEW software (National Instruments Corp, Singapore). The average
force values from three contractions were calculated for each papillary muscle segment.
The detailed buffer formulations are provided in the Supplementary Materials (Table S4).
Additionally, the method used to characterise Ca2+ sensitivity is also described in the
Supplementary Materials.
4.3. Measurement of Sarcomeric Protein Phosphorylation
During cardiac dissection for papillary muscle isolation, the left ventricles were excised
and snap frozen in liquid nitrogen prior to storing them at −80 ◦C. The frozen ventricles
were mechanically pulverised using a mortar and pestle and added to Laemmeli sample
buffer (62.5 mM tris, 2% SDS, 10% (v/v) glycerol, 50 mM dithiothreitol (DTT), 6.7 M Urea,
pH 6.8) at a ratio of 20 µL/mg. The lysate was mixed and quickly heated at 100 ◦C for
5 min to denature proteases and phosphoproteases. Prior to conducting gel electrophoresis,
the concentration of the lysate proteins was determined using a Micro BCA Protein Assay
Kit (Thermofisher Scientific, Waltham, MA, USA). Phos-tag polyacrylamide (Nard Institute
Ltd., Japan) gel was used to quantify sarcomeric protein phosphorylation levels. The
resolving and stacking gels (Table S5) were prepared and left to set for 90 min and 45 min,
respectively. Each well was loaded with 300 µg of lysate proteins. Gel electrophoresis
was conducted at 140 V for 150 min at room temperature. The electrophoresis tanks were
wrapped with cold (~4–15 ◦C) wet cloth to facilitate heat transfer away from the buffer, as
phos-tag gels are sensitive to high temperature and cause distortion to resolving protein
bands as a result [102]. Prior to protein transfer, the phos-tag gels were treated with transfer
buffer (25 mM tris, 192 mM glycine, 20% (v/v) methanol, pH 8.3) containing 10 mM EDTA
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for a total of 20 min (two sets of 10 min treatment with a change of buffer in between)
to improve transfer efficiency. After this, the gel was equilibrated in EDTA free-transfer
buffer for a total of 20 min (two sets of 10 min treatment and change of buffer in between).
A pore-sized PVDF membrane measuring 0.2 µm was used for transferred proteins to
adhere to. PVDF membranes were soaked in 100% methanol for activation. Proteins were
transferred at 400 mA for an hour at 4 ◦C. Blots containing transferred proteins were
blocked in 5% BSA in TBST for an hour and then incubated with 1◦ antibodies according
to the recommended dilutions in the product specifications. The incubation was carried
out overnight at 4 ◦C. The next day, excess antibodies were removed by washing the blots
with TBST for 30 min (change of buffer every 10 min). The blot was then incubated in 2◦
antibodies conjugated with HRP, for an hour at room temperature. After this, the blots were
exposed to chemiluminescence reagents (Bio-Rad Laboratories, Singapore). The oxidation
of the reagents was catalysed by HRP, resulting in a chemiluminescence signal (light at
425 nm) being emitted [103]. This signal was then detected by the BioRad ChemiDoc MP-
Imaging system and an image was captured immediately using the ImageLab5.2 software
(Biorad, Singapore). The formula to calculate the phosphorylation is stated below. The
details of the antibodies used are presented in Table S6. A comprehensive guide for using
Phos-tag gels is provided in [104].
Ratio of RLC phosphorylation =
intensity o f (1× 1P) + intensity o f (2× 2P)
intensity o f (0P + 1P + 2P)
4.4. Quantifications of Enzymes That Regulate RLC Phosphorylation
The methodology used to quantify enzyme expression was exactly the same as de-
scribed previously in Section 2.3. However, an ordinary polyacrylamide gel was used
instead of phos-tag gel. A proportion of 15% polyacrylamide gel was used to resolve MLCK
and ZIPK, while 10% was used to resolve MYPT2. The constituents of the gels are presented
in Table S7.
4.5. Expression and Purification of Recombinant RLC (rRLC)
The rRLC plasmid was donated by Professor Irving’s laboratory at King’s College
London. The expression and purification protocols were described in a previous study and
are detailed in the Supplementary Materials [11].
4.6. In Vitro rRLC Phosphorylation
Concentrated RLCs (1 mg/mL) were mixed with phosphorylation kinase buffer (PKB)
(25 mM HEPES, pH 7.1, 1 mM MgCl2, 200 mM NaCl, 1 mM DTT, 0.2 mM Na2ATP,
5 mM glycerol), 10 µg myosin light chain kinase (MLCK, Sigma M9197) and 10 µg zipper-
interacting protein kinase (ZIPK, Sigma D7194, St. Louis, MO, USA) at a volume ratio
of 800:200:1:8 (RLC:PKB:MLCK:ZIPK). The mixture was then incubated at 37 ◦C for two
hours, with MLCK and ZIPK being replenished with the same volume every half hour. The
phosphorylated RLCs were resolved in 10% polyacrylamide gel containing 25 µM phos-tag
molecules for 45 min at 180 V under room temperature, followed by the above-mentioned
Western blotting procedure. RLC phosphorylation levels were calculated using ImageJ,
showing that 51.7% of the recombinant RLCs were phosphorylated (figure not shown).
After this, they were aliquoted into small fractions and stored at −80 ◦C for long-term use.
4.7. Phosphorylated rRLC Exchange
Exchange buffer (10 mM Na2ATP, 20 mM Imidazole, 10 mM EGTA, 10 mM EDTA,
20 mM KH2PO4, 300 mM potassium propionate, 0.5 mM trifluoperazine, 5 mM DTT,
pH 6.5), phosphorylated rRLC and TnC (LeeBio, Maryland Heights, MO, USA) were
required for the exchange procedure. The use of the above-mentioned chemicals, primarily
involving trifluoperazine, induced a conformational change in native RLCs, resulting in it
dissociating from the myosin heavy chains [105], allowing phosphorylated recombinant
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RLCs to occupy the site. TnC is significantly reduced during permeabilisation and was
replenished to preserve muscle contractility [11,14,106]. The exchange procedure was
conducted at 20 ◦C. Permeabilised papillary muscle segments were incubated for a total of
45 min in exchange buffer containing 800 µM of phosphorylated rRLC and 57.8 µM of TnC
with a replenishment of 30 µL of exchange buffer (containing TnC and phosphorylated RLC)
every 15 min. To remove unbound phosphorylated rRLC after the exchange procedure,
the fibres were incubated in 57.8 µM TnC containing relaxing buffer for 10 min at 20 ◦C.
In the existing literature, the amounts of RLC used for exchange range between 30 µM
and 25 mM [11,107,108]. However, the exchange efficiency is comparable when 30 µM,
800 µM or 25 mM of RLC is used [11]. To calculate the exchange efficiency, five fibres
underwent exchange with 1◦ Rho·RLC only and another five underwent 1◦ Rho·RLC
and 2◦ unlbl·RLC exchange (Figure S4). The proteins from the fibres were extracted with
Laemmli buffer (3 µL/fibre) and resolved with 10% polyacrylamide–SDS gel for 1 h at
140 V (room temperature). The signal from the HRP-conjugated RLC was captured with
the BioRad ChemiDoc MP-Imaging system. The exchange efficiency was calculated using
the formula below. Using the above-mentioned protocol, the exchange efficiency of RLCs
in permeabilised papillary segments was 47%, as presented in Figure S4.
Exchange efficiency =
1◦Rho·RLCsignal − (1◦Rho·RLC ∧ 2◦unlbl·RLC)signal
1◦Rho·RLCsignal (1)
4.8. Statistical Analysis
Statistics were calculated using GraphPad Prism 7.2 (GraphPad Software, San Diego,
CA, USA). The normality of the sample populations was determined using Shapiro–Wilk’s
test and homogeneity was determined using the F-test, prior to conducting Student’s t-test.
One- or two-tailed Student’s t-tests were performed to determine statistical significance
between the means of the two groups. The normality of the sample populations was
determined using Shapiro–Wilk’s test and homogeneity by F-test, prior to conducting
Student’s t-test. If the sample populations were nonparametric, Mann–Whitney test was
employed; if they were parametric but not homogenous, Student’s t-test with Welch’s
correction was applied. Here, * p < 0.05, ** p < 0.01, *** p < 0.001
Ordinary one-way ANOVA was used to determine statistical differences among the
means of more than two sample populations that were parametric and homogenous. Brown–
Forsythe or Bartlett’s test were performed to verify homogeneity of results prior to ANOVA
test. If the sample populations were nonparametric, Kruskal-Wallis test was employed. If
the samples were parametric but not homogenous, Brown–Forsythe or Welch’s ANOVA
test was employed. All data are shown as means ± S.E.
5. Conclusions
This study suggests that RLC phosphorylation changes transiently to bring about a
compensatory effect of cardiac function. RLC phosphorylation also has the potential to
reverse contractile impairment stemming from cardiac disease. There are likely other key
players altering muscle contraction during HF progression. Thus, the interactions between
RLCs and the other players need to be elucidated to design an effective treatment for HF.
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